Sara Pilotto
YOU?
Author Swipe
View article: Managing lorlatinib-induced weight gain through a structured exercise intervention in an ALK+ NSCLC patient: a case report
Managing lorlatinib-induced weight gain through a structured exercise intervention in an ALK+ NSCLC patient: a case report Open
Background In non-small cell lung cancer (NSCLC), ALK tyrosine kinase inhibitors (TKIs) have been associated with significant weight gain, predominantly in fat tissues. To date, only one case report has evaluated the impact of pharmacologi…
View article: How a physical exercise program performed by patients may impact caregiver burden in cancer: a qualitative study
How a physical exercise program performed by patients may impact caregiver burden in cancer: a qualitative study Open
Purpose Caregivers of patients with metastatic cancer may be exposed to an overwhelming sense of burden. Physical exercise may help patients improve their physical condition, manage symptoms, and enhance their quality of life. Nevertheless…
View article: Detection and Monitoring ALK Gene Alterations through Liquid Biopsy in Advanced NSCLC Treated with Alectinib: Preliminary TANGIBLE Study Results
Detection and Monitoring ALK Gene Alterations through Liquid Biopsy in Advanced NSCLC Treated with Alectinib: Preliminary TANGIBLE Study Results Open
View article: Running session-conditioned human serum lowers prostate cancer cell spheroid formation
Running session-conditioned human serum lowers prostate cancer cell spheroid formation Open
Purpose Physical activity is associated with a lower mortality and recurrence risk in cancer, yet the underlying mechanisms remain unclear. This study aimed to evaluate the effects of running sessions on the tumorigenic potential of prosta…
View article: Periodizing Exercise Medicine Prescription for Patients with Cancer: A Narrative Opinion
Periodizing Exercise Medicine Prescription for Patients with Cancer: A Narrative Opinion Open
View article: Prognostic and predictive implications of tumor suppressor gene alterations in non-small cell lung cancer
Prognostic and predictive implications of tumor suppressor gene alterations in non-small cell lung cancer Open
View article: Impact of exercise in patients with pancreatic cancer across different treatment phases: A systematic review
Impact of exercise in patients with pancreatic cancer across different treatment phases: A systematic review Open
Although physical exercise may ameliorate sequelae of pancreatic cancer, further investigation is necessary to understand the real impact of exercise medicine interventions in this population and across different treatment phases.
View article: PI3K/mTORC2-RICTOR axis in early squamous non-small-cell lung cancer: genomics, molecular expression, and clinical relevance
PI3K/mTORC2-RICTOR axis in early squamous non-small-cell lung cancer: genomics, molecular expression, and clinical relevance Open
Background: Although considerable discoveries have been made in the genomic landscape of lung adenocarcinoma, to date, little is known regarding potential prognostic factors and altered pathways in resected squamous non-small-cell lung can…
View article: 146P Molecular characterization of head and neck squamous cell carcinoma: Driver and potential druggable alterations across anatomical subsites
146P Molecular characterization of head and neck squamous cell carcinoma: Driver and potential druggable alterations across anatomical subsites Open
View article: Low fT3/fT4 ratio as a proxy for muscle wasting in patients with advanced non-small cell lung cancer treated with pembrolizumab
Low fT3/fT4 ratio as a proxy for muscle wasting in patients with advanced non-small cell lung cancer treated with pembrolizumab Open
Background Loss of skeletal muscle mass may serve as a valuable indicator of treatment efficacy and survival in individuals with lung cancer undergoing immunotherapy. This investigation sought to pinpoint accessible markers that could refl…
View article: Effect of exercise on bone-related outcomes in patients with cancer affected by bone metastases or bone loss: a systematic review and meta-analysis
Effect of exercise on bone-related outcomes in patients with cancer affected by bone metastases or bone loss: a systematic review and meta-analysis Open
Our results suggest that, while exercise does not significantly increase BMD in patients with cancer and bone impairments when added to standard therapies, there are important variations across studies. High-intensity resistance and impact…
View article: Exercise and inflammation in female survivors of breast cancer: systematic review and meta-analysis with secondary mediation analysis on body composition
Exercise and inflammation in female survivors of breast cancer: systematic review and meta-analysis with secondary mediation analysis on body composition Open
Purpose Inflammation plays a key role in breast cancer recurrence and mortality by promoting tumor progression. Exercise significantly reduces pro-inflammatory markers such as IL-6, TNF-α, and CRP, potentially reducing mortality risk. Howe…
View article: Meta-Analysis Exploring Tyrosine Kinase Inhibitor-Induced Weight Gain in Oncogene-Addicted NSCLC
Meta-Analysis Exploring Tyrosine Kinase Inhibitor-Induced Weight Gain in Oncogene-Addicted NSCLC Open
Our findings confirmed the unique profile of lorlatinib regarding weight gain, regardless of patient characteristics. Considering the impressive prognostic horizons achievable with TKIs in oncogene-addicted NSCLC, adequate reporting in cli…
View article: Uncovering common transcriptional features shared by mature peripheral blood PMN-MDSCs and tumor-infiltrating neutrophils in humans
Uncovering common transcriptional features shared by mature peripheral blood PMN-MDSCs and tumor-infiltrating neutrophils in humans Open
Human polymorphonuclear-myeloid-derived suppressor cells (PMN-MDSCs) consist of circulating low-density neutrophils (LDNs) characterized by the ability to inhibit T-cell responses. In previous studies, we demonstrated that the mature fract…
View article: Cardiac autonomic dysfunction in patients with cancer: exploring the role of physical exercise
Cardiac autonomic dysfunction in patients with cancer: exploring the role of physical exercise Open
View article: ARID1A mutational status in non-small cell lung cancer: from molecular pathology to clinical implications with a focus on the relationships with EGFR
ARID1A mutational status in non-small cell lung cancer: from molecular pathology to clinical implications with a focus on the relationships with EGFR Open
Lung cancer is the most frequently diagnosed malignancy worldwide and remains the leading cause of cancer-related mortality. Non-small-cell lung cancer (NSCLC) is the most prevalent type of lung cancer, with epidermal growth factor recepto…
View article: Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancer
Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancer Open
View article: Further-Line Treatment With Amivantamab Plus Lazertinib in EGFR-Mutant NSCLC: New Answers to Old Questions?
Further-Line Treatment With Amivantamab Plus Lazertinib in EGFR-Mutant NSCLC: New Answers to Old Questions? Open
View article: Physical activity guidelines in oncology: A systematic review of the current recommendations
Physical activity guidelines in oncology: A systematic review of the current recommendations Open
This review aims to summarize the recommendations endorsed by scientific societies regarding physical activity for patients with cancer. A systematic search was conducted to identify guidelines endorsed by scientific societies and publishe…
View article: Current diagnostic and therapeutical approaches to bone metastases in patients with non-small cell lung cancer: A cross-sectional study
Current diagnostic and therapeutical approaches to bone metastases in patients with non-small cell lung cancer: A cross-sectional study Open
Lung-cancer dedicated clinicians pay great attention to bone metastases-related diagnostic, bone-targeted agents, and radiotherapy issues, whereas the integration of supportive care approaches seem less standardized.
View article: Overcome the Fear of Exercise in Patients With Bone Metastases: A Qualitative Study on Patients' Perception
Overcome the Fear of Exercise in Patients With Bone Metastases: A Qualitative Study on Patients' Perception Open
Purpose This qualitative study aimed to explore the experiences of patients with cancer and bone metastases who participated in a personalized exercise program. Methods Individual interviews were conducted through purposeful sampling of pa…
View article: Supplementary Table S1 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
Supplementary Table S1 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial Open
Supplementary Table 1. Baseline and disease characteristics of patients.
View article: Supplementary Table S6 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
Supplementary Table S6 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial Open
Supplementary Table 6. Clinical characteristics of MAPK1/MAPK3-positive vs -negative patients in the Dana Farber Cancer Institute validation cohort.
View article: Supplementary Figure S8 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
Supplementary Figure S8 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial Open
Supplementary Figure 8. Percentage (A) and number (B) of patients with mutations in genes belonging to MAPK1/3 signaling pathway and (C) an overview of MAPK1/3 pathway mutations and copy number variation.
View article: Supplementary Figure S3 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
Supplementary Figure S3 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial Open
Supplementary Figure 3. Median duration of response. NI group (blue line) vs N-CT group (red line). N-CT: nivolumab plus platinum-based chemotherapy; NI: nivolumab plus ipilimumab.
View article: Supplementary Table S4 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
Supplementary Table S4 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial Open
Supplementary Table 4. Summary of adverse events
View article: Supplementary Figure S5 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
Supplementary Figure S5 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial Open
Supplementary Figure 5. Exploratory analysis of median overall survival (A-C) and progression-free survival (B-D) according to treatment in PD-L1 low (A-B) and PD-L1 high (C-D) patients. NI group (yellow line) vs N-CT group (blue line).
View article: Supplementary Figure S6 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
Supplementary Figure S6 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial Open
Supplementary Figure 6. Percentage of patients having mutations in MAPK1/MAPK3 signaling and individual genes.
View article: Supplementary Figure S13 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
Supplementary Figure S13 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial Open
Supplementary Figure 13. Overall survival in patients who did not receive PD-(L)1 blockade at the Dana-Farber Cancer Institute. MAPK1/3-negative (yellow line; n = 28) vs MAPK1/3-positive (blue line; n = 51).
View article: Supplementary Figure S15 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
Supplementary Figure S15 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial Open
Supplementary Figure 15. Median overall survival (A) and progression-free survival (B) according to TP53 mutation status. (A) TP53 (mutant; blue line; n = 41) vs TP53 (wild-type) (yellow line; n = 33). (B) TP53 (mutant; blue line; n = 41) …